Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Cash from Financing Activities (2016 - 2025)

Karyopharm Therapeutics' Cash from Financing Activities history spans 14 years, with the latest figure at $29.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 4266.47% year-over-year to $29.7 million; the TTM value through Dec 2025 reached $30.4 million, up 3117.37%, while the annual FY2025 figure was $30.0 million, 27.85% down from the prior year.
  • Cash from Financing Activities reached $29.7 million in Q4 2025 per KPTI's latest filing, up from $680000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $155.8 million in Q4 2022 to a low of $16000.0 in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $24.9 million, with a median of $3.6 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: soared 36143.75% in 2022, then crashed 99.83% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $896000.0 in 2021, then surged by 17293.19% to $155.8 million in 2022, then plummeted by 99.83% to $264000.0 in 2023, then soared by 157.58% to $680000.0 in 2024, then soared by 4266.47% to $29.7 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Cash from Financing Activities are $29.7 million (Q4 2025), $680000.0 (Q4 2024), and $264000.0 (Q4 2023).